Movement Alert｜Atai Beckley Rises 32.93% in Regular Trading, Eli Lilly to Acquire Company for Up to $3.8 Billion

Market Focus

Jul 17

On July 16, Atai Beckley surged 32.93% in regular trading, trading at $7.125/share, with turnover of $910 million. The sharp rally was driven by the announcement that pharmaceutical giant Eli Lilly will acquire the clinical-stage biotech company for up to $3.8 billion at a premium.

According to multiple reports, Eli Lilly confirmed the acquisition of Atai Beckley to strengthen its presence in mental health therapeutics, particularly targeting treatment-resistant depression and other complex psychiatric disorders. Prior to the deal announcement, Atai Beckley had a market capitalization of approximately $1.97 billion, implying a significant premium in the transaction. The deal aims to integrate Atai Beckley's research pipeline and technical expertise in psychedelic-based therapies to accelerate the development of novel treatments.

Atai Beckley is a clinical-stage biopharmaceutical company focused on developing therapeutics for depression, anxiety, addiction, and other mental health disorders. Its pipeline includes BPL-003, an intranasal formulation in Phase 2 clinical studies for treatment-resistant depression, among other candidates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1101148767"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101148767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101148767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 01:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101148767","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Atai Beckley Rises 32.93% in Regular Trading, Eli Lilly to Acquire Company for Up to $3.8 Billion","media":"Market Focus","content":"<p><p>On July 16, Atai Beckley surged 32.93% in regular trading, trading at $7.125/share, with turnover of $910 million. The sharp rally was driven by the announcement that pharmaceutical giant Eli Lilly will acquire the clinical-stage biotech company for up to $3.8 billion at a premium.</p><p>According to multiple reports, Eli Lilly confirmed the acquisition of Atai Beckley to strengthen its presence in mental health therapeutics, particularly targeting treatment-resistant depression and other complex psychiatric disorders. Prior to the deal announcement, Atai Beckley had a market capitalization of approximately $1.97 billion, implying a significant premium in the transaction. The deal aims to integrate Atai Beckley's research pipeline and technical expertise in psychedelic-based therapies to accelerate the development of novel treatments.</p><p>Atai Beckley is a clinical-stage biopharmaceutical company focused on developing therapeutics for depression, anxiety, addiction, and other mental health disorders. Its pipeline includes BPL-003, an intranasal formulation in Phase 2 clinical studies for treatment-resistant depression, among other candidates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Atai Beckley Rises 32.93% in Regular Trading, Eli Lilly to Acquire Company for Up to $3.8 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Atai Beckley Rises 32.93% in Regular Trading, Eli Lilly to Acquire Company for Up to $3.8 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 01:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, Atai Beckley surged 32.93% in regular trading, trading at $7.125/share, with turnover of $910 million. The sharp rally was driven by the announcement that pharmaceutical giant Eli Lilly will acquire the clinical-stage biotech company for up to $3.8 billion at a premium.</p><p>According to multiple reports, Eli Lilly confirmed the acquisition of Atai Beckley to strengthen its presence in mental health therapeutics, particularly targeting treatment-resistant depression and other complex psychiatric disorders. Prior to the deal announcement, Atai Beckley had a market capitalization of approximately $1.97 billion, implying a significant premium in the transaction. The deal aims to integrate Atai Beckley's research pipeline and technical expertise in psychedelic-based therapies to accelerate the development of novel treatments.</p><p>Atai Beckley is a clinical-stage biopharmaceutical company focused on developing therapeutics for depression, anxiety, addiction, and other mental health disorders. Its pipeline includes BPL-003, an intranasal formulation in Phase 2 clinical studies for treatment-resistant depression, among other candidates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATAI","symbol_name":"Atai Beckley Inc","start_time":0,"source_url":"","article_id":"1101148767","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101148767","pubTimestamp":1784222112,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, Atai Beckley surged 32.93% in regular trading, trading at $7.125/share, with turnover of $910 million. The sharp rally was driven by the announcement that pharmaceutical giant Eli Lilly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATAI":"Atai Beckley Inc"},"translate_title":"走势警报|Atai Beckley 常规交易上涨 32.93%，礼来公司将以高达 38 亿美元收购公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATAI":1},"content_text":"On July 16, Atai Beckley surged 32.93% in regular trading, trading at $7.125/share, with turnover of $910 million. The sharp rally was driven by the announcement that pharmaceutical giant Eli Lilly will acquire the clinical-stage biotech company for up to $3.8 billion at a premium.According to multiple reports, Eli Lilly confirmed the acquisition of Atai Beckley to strengthen its presence in mental health therapeutics, particularly targeting treatment-resistant depression and other complex psychiatric disorders. Prior to the deal announcement, Atai Beckley had a market capitalization of approximately $1.97 billion, implying a significant premium in the transaction. The deal aims to integrate Atai Beckley's research pipeline and technical expertise in psychedelic-based therapies to accelerate the development of novel treatments.Atai Beckley is a clinical-stage biopharmaceutical company focused on developing therapeutics for depression, anxiety, addiction, and other mental health disorders. Its pipeline includes BPL-003, an intranasal formulation in Phase 2 clinical studies for treatment-resistant depression, among other candidates.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}